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m1060133 AreAcuteandLateClinicalOutcomeaintheElderlyDifferentintheNewDeviceAngioplasty
Era?
A. Abizaid, C.E. Clark, J.J. Popma, A.D. Pichard, K.M. Kent, L.F.Satler,
J.R. Laird, G.S. Mintz, J. “Lindaay,T.A. Bucher, M.B. Leon. Washington
Hospital Centec Washington, DC, USA
Important decisione regarding resource allocation will depend upon risk-
benefit analyses in specific patient populations, especially the elderly. To
determine clinical outcome variablee after cetheter-basad coronary interven-
tional procadurea in theelderiy, we analyzed 5,355 consecutive patients from
1992 to 1996 treated using balloon PICA or new device angioplasty (60%).
in-HosDitelEvents <70 we 70-60yrs >80 yre P
(N =3860) (N= 1265) (N =230)
PrOcsuccsss 96”/n 96% 95% NS
Death 0.8”/0 2.4”/n 4,2%
Q-wave Ml
<0.0001
0.9% 0.6% 1,9% NS
CASG 1.4% 1.2% 0.7”/’0 NS
Vaec comp 5.0% 6.0.% 6.7% <0.0001
Stroke 0.37. 0.7% 2.30/4 <0.0001
CHF 1.9% 4.3”h 6.9% <0.0001
Renal failure 2.3% 6.2°A 7.3”/. <0.0001
Vaacularcomplicationa(Vaac comp) = surgicalrepair+ transfusion
During long-term (=- 6 months) clinical follow-up, there was a stepwiae
increase in death in the elderly (2.7% vs. 6.5Y0vs. 11.4Y0,p < 0.0001), mainly
due to non-cardiac causes, but no increase in Mlsor repeat revascularization
events. We Conclude: In the new device era, elderfy patients (1) have ex-
cellent procedure succees, but higher in-hospital mortality and non-cardiac
mmplicetions; and (2) Iata outcomes indicate continued high mortality, but
similar repeat revascularization events.
m1060134 TherapeuticUltrasoundCoronaryAngioplasty-OnlyDotterEffect?
C.W. Harem, D.H. Koschyk, J. Reimers, W. Steffen, T. Meinertz. University
Hospitel Hamburg, Dept. of Cardiology Hamburg, Germany
Coronary ultrasound angioplasty (USA) is a new therapeutic interventional
device for coronary arteriea. Energy of 16-20 W at 19.5 kHz is supplied
through a 1.2 or 1.7 mm ball tip catheter during longitudinal vibrations of
16-20 wm. To assess the effect on vessel wall and plaque, intravascular ul-
trasound imaging waaperfofmacf in21 consecutive patients (pts.) undergoing
USA with the 1.7 mm catheter for symptomatic coronary artery diaeaae.
Results: After USA in 19/21 lesions with mixed plaque configuration tha
lumen diameter was 1.7+ 0.2 mm. ln21eeionswith eoffthr0mbotic material an
eccentric lumen enlargement wae found (2.2 and 2.8 x 1.7 mm diameter).
In 19/21 leaions the inner plaque contour was found to have an unusual
sharp contour. [n 7 Iesiona a new circular achodens phenomenon raaching
from the borderline of the inner lumen/intima up to 0.3 mm into the plague
wee detected. Thare wae no evidence of dissection but intima splitting in 4
leeions.Afteradjunctive Iowpreasure PTCAin 19/21 Iesionsthe inner contour
remained smooth in 8 lesions, 1 dissection and 3 new intima splittings were
detected.
Summary: 1)After coronary ultrasound angioplasty a smooth inner con-
tour of the intima is regularly found. 2) In about one third of the Iesiona a
new circular echodens zone at the inner border (intimdinner lumen) can be
aasessed. 3) The lumen size after ultrasound angioplasfy has the size of the
catheter in patients with mixed plaque; it is more increased in soft plaque
Iesione.
Cone/usion:There isadirecteffecf of thecoronafy ultrasound angioplasfy
to the inner lumerVplaque that can not be explained with dotter effect alone.
H1060149 CuttingBalloonAngioplastyva.PlainOldBalloonAngioplaetyRandomizedStudyinType
B/Clesions(CAPAS)
M. Funamoto, E. Tsuchikane, K. Moriguchi, S. Oteuji, H. Tateyama,
N. Awata. Oeaka Madicel Centarfor CanCerar7dCardiovascular Diseaaas,
Osaka, Japan
To evaluate the efficacy and safety of cutting balloon angioplasty (CB) for
type B/C lesions, a prospective randomized trial was designed. This study
started in Nov. 1995 and 151 Iasions were enrolled by Aug. 1996. Inclusion
criteria were as follows; type B/C lesions (ACC/AHA claaeificetion), reference
diameter (RD) <2.6 mm. Exclusion criteria were ae follows; heavily calcified
lesion, severely bant lesion and AMI culprit lesion. Furthermore, lesions with
incomplete balloon expansion or interrupted and aevere dissection requir-
ing etenting were defined as drop-outs. 151 lesions were divided into two
groupe (CB: 76, POBA: 75 lesions). Eligible lesions were 76% (58i76) in
CB and 77% (56i75) in POBA. Quantitative Coronaty angiography (QCA)
was to be performed at pre, peat-PTCA and 3 months follow-up (3 M) using
Cardiovascular Measurement System Ver.3 (CMS). Baeeline QCAdate were
not different in the 2 groups [RD; 2.1 + 0.3: 2.2 + 0.4 mm, minimal lumen
diameter (MLD); 0.64= 0.4: 0.7* 0.2 mm, % diameter stenoeie (% DS); 70
+ 15: 75* 10% (CB: POBA)]. Post-QCA date were also not different [MLD;
1.6 + 0.4: 1.5+ 0.4 mm, % DS; 24 + 14:32+ 13%, BalloerdArtery ratio; 1.3
+0.2: 1.2 l 0.2 (CB: POBA)]. There were no major in-hoapital complications
in the 2 groupe. 3M-QCA data were not different [MLD; 1.2 * 0.4: 1.2 & 0.4
mm, % DS; 46 + 14: 53+ 13% (CB: POBA)]. Target leeion revaecularization
(1’LR)rate was 30% (13/44) in CB and 41% (16/44) in POBA.
Conclusion: Cutting balloon angioplasty was performed aafely compared
to plain old balloon angioplasty for type B/C Ieaions. Ae for initial suoceas,
there were no remarkable differences between the 2 groups. But, 3 M data
(TLR) would suggest CB for typa B/C lesions may reduce rastenoeia.
-[ Clini.aiEvakIatiOnOftheCOrOnaf’YpU,,tJaC~
AtheractomyCathetar:ProceduralResuftsand
LataClinicalFollow-up
A.J. Carter, J.R. Laird, P.D.German, P.Gurczak, M.A. Garcia, A. Farb,
R. Virmani, A.J. Larrsky,.J.J. Popma, T.A. Fischell. Wa/ter Reed Army
Medical Center and Washington Hospital Centec Washington, DC, USA
The coronary Pullback Atherectomy Catheter (PAC) is a novel atherectomy
device with a 360 degree cutting circumference designed to exciee plaque
using a single retrograde paes through the lesion. We evaluated the aafety
and clinical efficacy of PAC in 40 patients with 42 lesions (LAD, n = 16; LCX,
n = 10; RCA, n = 13; SVG, n = 3). Quantitative coronary angiography was
completed at baseline, post PAC, after adjunetive therapy and at 6 months
post-procadure.
MLD (mm) % Stenosis
Baselina 0,93 + 0.29 69& 10
Peat-PAC 1.77+ o.51t 46+ 13t
Final 2.76 & 0.58t 17* at
6 Months* 1.75 & 0.56t 40+ 16t
*Data from 11 patients;tp <0.001 versus baaelina
Initial procedural success (< 50%diameterstenosis, without death, QWMI
or CABG) was achieved in all ceaes. Plaque (mean tiasue weight 6.8 l 9.0
mg) was removed from 40 of 42 (95%) lesions. The weight of the excised
tissue positively correlated with the PAC to artery ratio (r= 0.58, p = 0.0t17).
On histology,media oradventitia was identified in 24 of 40 (60Y0)apecimene.
Adjunctive therapy was required in all cases. Stent placement was performed
in 23 patients to optimize angiographic results and to treat 2 acute veasel
closures. CK-MB enzyme elevations ? 2 times normal occurred in 4 patienta.
At a mean of 7 months follow-up there were no deaths or QWMI. Target
lesion revascularizetion was required in 5 (12.5%) patienta.
Conclusions: PAC in conjunction with PTCA or stenting is aafe and effec-
tive for the treatment of symptomatic obstructive lesions in coronary arteries.
Late clinical and angiographic follow-up in this phase I study are nearing
completion.
1060-151 DoasGandarAffectOutcomein tha Naw
Approachesto CoronaryIntervention(NACI)
Ragistry
A.J. Lensky, E. Kennard, S.E. Yeung, R. Mehran, J.J. Popma, G. Harvey,
N.V. Summera, T. Conway, S. Russo, M.B. Leon, T. Robertson, K. Detre.
Univeraityof Pittsburgh, PA, USA, Washington Hospital Centac
Washington, DC, USA
Increased risk for procedural mortality was shown in women after balloon
PTCA in the 1965-86 NHLBI PTCA Registry. To assess the procedural
and late risk for women after planned new device angioplaafy (atherecfomy,
Men Woman
Number: Patiant4esion 1963/2216 1076/121S
AHNACC: A-BJIS2-C 29iTl 31/69
Dissection> A: PrelWorst 3/17 3/20
Referancediameter mm 3.16 3.04t
MLD Pre/Finalmm 0.91/2.45 0.94t/2.36t
‘IoStenosiaPrelFinal 71/24 69/24
Angiographicsuccees % 87 62$
Early CABG %JDeathO/. f ,61/0.96 2.97t/l.30
F/U CASG %/Death% 11.3/ 5.8 11.0/5.5
F/U Q-Ml%/RePTCA % 2.2123.7 1.6/20,9
Any F/U Death/QMl/Revaac ‘A 40.4 35.1*
